Gary A. Gintant
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gary A. Gintant has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Bryan F. Cox
6 shared publicationsZhi Su
6 shared publications- Ruth L. Martin
Abbott Laboratories, Abbot Park, IL, USA
4 shared publications Kathryn Houseman
3 shared publications- Xiaoqin Liu
Department of Integrative Pharmacology, Abbott, 100 Abbott Park Road, Abbott Park, IL 60064-6119, USA
3 shared publications Gilbert J. Diaz
2 shared publications
Latest Publications
- 1 January 2015
- Published by Springer Nature
- Vol. 229, 47-64
In Vitro Early Safety Pharmacology Screening: Perspectives Related to Cardiovascular Safety
In vitro screening for cardiovascular safety liabilities of novel drug candidates presents a challenge for the pharmaceutical industry. Such approaches rely on detecting pharmacologic effects on key components of complex integrated system early in drug discovery to define potential safety liabilities. Key to such studies are the concepts of hazard identification vs. risk assessment, drug specificity vs. selectivity, and an appreciation of the challenges faced when attempting to translate in vitro findings to preclinical in vivo as well as clinical effects. This chapter defines some key aspects of early safety pharmacology screening for cardiovascular liabilities, citing studies of two key depolarizing cardiac currents (fast sodium current and L-type calcium current) as examples linked to effects on cardiac conduction and repolarization.
- 1 January 2015
- Published by Springer Nature
- Vol. 229, 47-64
In Vitro Early Safety Pharmacology Screening: Perspectives Related to Cardiovascular Safety
In vitro screening for cardiovascular safety liabilities of novel drug candidates presents a challenge for the pharmaceutical industry. Such approaches rely on detecting pharmacologic effects on key components of complex integrated system early in drug discovery to define potential safety liabilities. Key to such studies are the concepts of hazard identification vs. risk assessment, drug specificity vs. selectivity, and an appreciation of the challenges faced when attempting to translate in vitro findings to preclinical in vivo as well as clinical effects. This chapter defines some key aspects of early safety pharmacology screening for cardiovascular liabilities, citing studies of two key depolarizing cardiac currents (fast sodium current and L-type calcium current) as examples linked to effects on cardiac conduction and repolarization.
- Open Access
- 9 July 2012
- Published by Wiley in British Journal of Pharmacology
- Vol. 167 (5) , 929-931
Ions, equations and electrons: the evolving role of computer simulations in cardiac electrophysiology safety evaluations
Reliable preclinical cardiac safety evaluations of drug candidates are essential for selecting the best therapeutic agents. Advanced automated patch clamp technologies now allow for characterizing drug effects on multiple cardiac currents, enabling subsequent simulations of integrated electrophysiological responses on cellular, tissue and organ levels. In this issue, Miramset al. summarize the strengths and limitations of models and simulations predicting drug‐induced electrophysiological responses, emphasizing delayed repolarization and Torsades de Pointes pro‐arrhythmia. The utility of computational approaches is contingent upon realistic models of ventricular electrophysiology, robust characterization of drug‐channel interactions and an understanding of channel‐myocyte interactions and pro‐arrhythmic mechanisms. Simulations evaluating effects on repolarization (hazard identification) should aid in selecting safer drug candidates early in drug discovery, while simulations evaluating risk of Torsades de Pointes (incorporating known risk factors) should quantify pro‐arrhythmic risk and reduce the need for costly clinical QT studies later in development. The wider adoption of realistic models and simulation studies will depend on simulation performance compared with ‘gold standard’ clinical findings.LINKED ARTICLEThis article is a commentary on Miramset al., pp. 932–945 of this issue. To view this paper visithttp://dx.doi.org/10.1111/j.1476‐5381.2012.02020.x
- 9 July 2012
- Published by Wiley in British Journal of Pharmacology
- Vol. 167 (5) , 929-931
Open AccessIons, equations and electrons: the evolving role of computer simulations in cardiac electrophysiology safety evaluations
Reliable preclinical cardiac safety evaluations of drug candidates are essential for selecting the best therapeutic agents. Advanced automated patch clamp technologies now allow for characterizing drug effects on multiple cardiac currents, enabling subsequent simulations of integrated electrophysiological responses on cellular, tissue and organ levels. In this issue, Miramset al. summarize the strengths and limitations of models and simulations predicting drug‐induced electrophysiological responses, emphasizing delayed repolarization and Torsades de Pointes pro‐arrhythmia. The utility of computational approaches is contingent upon realistic models of ventricular electrophysiology, robust characterization of drug‐channel interactions and an understanding of channel‐myocyte interactions and pro‐arrhythmic mechanisms. Simulations evaluating effects on repolarization (hazard identification) should aid in selecting safer drug candidates early in drug discovery, while simulations evaluating risk of Torsades de Pointes (incorporating known risk factors) should quantify pro‐arrhythmic risk and reduce the need for costly clinical QT studies later in development. The wider adoption of realistic models and simulation studies will depend on simulation performance compared with ‘gold standard’ clinical findings.LINKED ARTICLEThis article is a commentary on Miramset al., pp. 932–945 of this issue. To view this paper visithttp://dx.doi.org/10.1111/j.1476‐5381.2012.02020.x
- 1 April 2012
- Published by Elsevier in Life Sciences
- Vol. 90 (15-16) , 607-611
Characterization of A-935142, a hERG enhancer, in the presence and absence of standard hERG blockers
- 1 April 2012
- Published by Elsevier in Life Sciences
- Vol. 90 (15-16) , 607-611
Characterization of A-935142, a hERG enhancer, in the presence and absence of standard hERG blockers
- 5 March 2011
- Published by Springer Nature
- p. 627-638
Preclinical Drug Safety and Cardiac Ion Channel Screening
- 5 March 2011
- Published by Springer Nature
- p. 627-638
Preclinical Drug Safety and Cardiac Ion Channel Screening
- 2 February 2011
- Published by Elsevier in Biophysical Journal
- Vol. 100 (3) , 430a-431a
Drug-Induced hERG Current Enhancement is Modulated by Extracellular Proton and Potassium
- 2 February 2011
- Published by Elsevier in Biophysical Journal
- Vol. 100 (3) , 430a-431a
Drug-Induced hERG Current Enhancement is Modulated by Extracellular Proton and Potassium
- 1 February 2011
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 129 (2) , 109-119
An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation
- 1 February 2011
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 129 (2) , 109-119
An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation
- 1 February 2009
- Published by Elsevier in Biophysical Journal
- Vol. 96 (3) , 485a
Electrophysiologic Characterization of a Complex hERG Channel Activator
- 1 February 2009
- Published by Elsevier in Biophysical Journal
- Vol. 96 (3) , 485a
Electrophysiologic Characterization of a Complex hERG Channel Activator
- 1 February 2009
- Published by Elsevier in Biophysical Journal
- Vol. 96 (3) , 263a
Do hERG Enhancers and Blockers Compete?
- 1 February 2009
- Published by Elsevier in Biophysical Journal
- Vol. 96 (3) , 263a
Do hERG Enhancers and Blockers Compete?
- 1 August 2008
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 119 (2) , 199-209
Preclinical Torsades-de-Pointes Screens: Advantages and limitations of surrogate and direct approaches in evaluating proarrhythmic risk
- 1 August 2008
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 119 (2) , 199-209
Preclinical Torsades-de-Pointes Screens: Advantages and limitations of surrogate and direct approaches in evaluating proarrhythmic risk
- Open Access
- 1 January 2006
- Published by SAGE Publications in Toxicologic Pathology
- Vol. 34 (1) , 81-90
Utility of hERG Assays as Surrogate Markers of Delayed Cardiac Repolarization and QT Safety
HERG (human-ether-a-go-go-related gene) encodes for a cardiac potassium channel that plays a critical role in defining ventricular repolarization. Noncardiovascular drugs associated with a rare but potentially lethal ventricular arrhythmia (Torsades de Pointes) have been linked to delayed cardiac repolarization and block of hERG current. This brief overview will discuss the role of hERG current in cardiac electrophysiology, its involvement in drug-induced delayed repolarization, and approaches used to define drug effects on hERG current. In addition, examples of hERG blocking drugs acting differently (i.e., overt and covert hERG blockade due to multichannel block) together with the utility and limitations of hERG assays as tools to predict the risk of delayed repolarization and proarrhythmia are discussed.
- 1 January 2006
- Published by SAGE Publications in Toxicologic Pathology
- Vol. 34 (1) , 81-90
Open AccessUtility of hERG Assays as Surrogate Markers of Delayed Cardiac Repolarization and QT Safety
HERG (human-ether-a-go-go-related gene) encodes for a cardiac potassium channel that plays a critical role in defining ventricular repolarization. Noncardiovascular drugs associated with a rare but potentially lethal ventricular arrhythmia (Torsades de Pointes) have been linked to delayed cardiac repolarization and block of hERG current. This brief overview will discuss the role of hERG current in cardiac electrophysiology, its involvement in drug-induced delayed repolarization, and approaches used to define drug effects on hERG current. In addition, examples of hERG blocking drugs acting differently (i.e., overt and covert hERG blockade due to multichannel block) together with the utility and limitations of hERG assays as tools to predict the risk of delayed repolarization and proarrhythmia are discussed.